西格列汀联合胰岛素治疗1型脆性糖尿病的效果及安全性  

Efficacy and safety of Sitagliptin combined with insulin in the treatment of type 1 brittle diabetes

作　　者：刘娇[1] 邢晓磊[2] 张敏 吕晶[1] 万蒙 杨杨[2] LIU Jiao;XING Xiaolei;ZHANG Min;LYU Jing;WAN Meng;YANG Yang(Clinical College, Wuhan University of Science and Technology, Hubei Province, Wuhan 430064, China;Department of Endocrinology, Tianyou Hospital, Wuhan University of Science and Technology, Hubei Province, Wuhan 430064, China)

机构地区：[1]武汉科技大学临床学院,湖北武汉430064 [2]武汉科技大学附属天佑医院内分泌科,湖北武汉430064

出　　处：《中国医药导报》2019年第11期134-137,共4页China Medical Herald

基　　金："十三五"国家重点研发计划项目(2017YFD0400300)

摘　　要：目的探讨西格列汀联合胰岛素治疗1型脆性糖尿病的临床疗效和安全性。方法选取武汉科技大学附属天佑医院2016年9月～2018年4月收治的80例1型脆性糖尿病患者,采用奇偶法随机分为对照组和观察组,每组各40例。对照组采用胰岛素治疗,观察组在对照组治疗基础上联合西格列汀进行治疗,疗程为3个月,比较两组患者血糖指标、胰岛功能、不良反应发生率及低血糖发生次数。结果治疗前两组空腹血糖(FBG)、2 h餐后血糖(2 h PBG)、糖化血红蛋白(HbA1c)比较,差异无统计学意义(P> 0.05),治疗后两组FBG、2 h PBG、HbA_(1c)指标较本组治疗前降低(P <0.05),且观察组FBG、2 h PBG、HbA1c低于对照组(P <0.05)。治疗前两组空腹C肽及餐后2 h C肽比较,差异无统计学意义(P> 0.05),治疗后两组空腹C肽及餐后2 h C肽较治疗前升高(P <0.05),且观察组空腹C肽及餐后2 h C肽高于对照组(P <0.05)。观察组不良反应发生率、低血糖发生次数明显低于对照组(P <0.05)。结论采用胰岛素治疗1型脆性糖尿病患者可以降低血糖,改善胰岛功能,但采用西格列汀联合胰岛素治疗1型脆性糖尿病患者,其降糖及改善胰岛功能效果更显著,且低血糖事件发生少,能够很好地稳定患者血糖,不良事件发生率低,具有较高的安全性,值得临床中推广应用。Objective To investigate the clinical efficacy and safety of Sigliptin combined with insulin in the treatment of type 1 brittle diabetes mellitus. Methods A total of 80 patients with type 1 brittle diabetes were selected from September 2016 to April 2018 in Tianyou Hospital, Wuhan University of Science and Technology. They were divided into control group and observation group by odd even random method, with 40 patients in each group. The control group was treated with insulin, while the observation group was treated with Sigliptin on the basis of the control group. The course of treatment was three months. The blood sugar index, islet function, incidence of adverse reactions and frequency of hypoglycemia were compared between the two groups. Results There was no significant difference in FBG, 2 h PBG and HbA1c between the two groups before treatment (P > 0.05). After treatment, FBG, 2 h PBG and HbA1c in the two groups were lower than those before treatment (P < 0.05), and PBG, 2 h PBG and HbA1c in the observation group were lower than those in the control group (P < 0.05). There was no significant difference in fasting C-peptide and postprandial 2 h C-peptide between the two groups before treatment (P > 0.05). After treatment, the fasting C-peptide and postprandial 2 h C-peptide in the two groups were higher than those before treatment (P < 0.05), and the fasting C-peptide and postprandial 2 h C-peptide in the observation group were higher than those in the control group (P < 0.05). The incidence of adverse reactions and the frequency of hypoglycemia in the observation group were significantly lower than those in the control group (P < 0.05). Conclusion Insulin can reduce blood sugar and improve islet function in patients with type 1 brittle diabetes mellitus, but the effect of Sitagliptin combined with insulin in the treatment of type 1 brittle diabetes mellitus is more significant, and the occurrence of hypoglycemic events is less, which can stabilize blood sugar well, and the incidence of adverse events is low

关 键 词：西格列汀 胰岛素 1型脆性糖尿病 

分 类 号：R587.1[医药卫生—内分泌]